Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
A8MTI9

UPID:
PRS47_HUMAN

ALTERNATIVE NAMES:
Serine protease 47, pseudogene

ALTERNATIVE UPACC:
A8MTI9

BACKGROUND:
The protein known as Putative serine protease 47, alternatively named Serine protease 47 pseudogene, is a subject of scientific intrigue. Its classification as a pseudogene does not diminish its potential significance in protein research. Serine proteases play critical roles in various biological systems, including metabolism, immunity, and coagulation, making them key targets in therapeutic research.

THERAPEUTIC SIGNIFICANCE:
Exploring the function of Putative serine protease 47 could lead to groundbreaking therapeutic approaches. Given its relation to the serine protease family, it may be involved in key physiological processes, positioning it as a valuable target for the development of novel treatments.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.